Irvine-based molecular diagnostic company CombiMatrix Corp.’s shares shot up Friday after two studies published in the New England Journal of Medicine validated its test offerings.
CombiMatrix’s shares were up 218% to a market value of $7 million in midday trading.
The company said the studies favored chromosomal microarray analysis,–CombiMatrix’s testing specialty—over traditional karyotype tests for genetic prenatal diagnosis and genetic analysis of stillbirths.
CombiMatrix is a molecular diagnostic laboratory offering DNA-based testing services to the prenatal, pediatric and oncology markets.
